Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group

David Scott Miller, John A. Blessing, Diane C. Bodurka, Albert J. Bonebrake, John O. Schorge

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint Dive into the research topics of 'Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group'. Together they form a unique fingerprint.

Medicine & Life Sciences